Group One Trading, L.P. Spero Therapeutics, Inc. Transaction History

Group One Trading, L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.0 - $1.47 $29,600 - $43,512	-29,600 Reduced 86.58%	4,590 $6,000
Q3 2023 Nov 09, 2023	SELL	$1.2 - $1.63 $69,336 - $94,181	-57,780 Reduced 62.82%	34,190 $41,000
Q2 2023 Aug 09, 2023	BUY	$1.42 - $1.95 $6,909 - $9,488	4,866 Added 5.59%	91,970 $133,000
Q1 2023 May 12, 2023	BUY	$1.35 - $2.0 $109,840 - $162,726	81,363 Added 1417.23%	87,104 $126,000
Q4 2022 Feb 09, 2023	SELL	$1.55 - $2.12 $76,506 - $104,641	-49,359 Reduced 89.58%	5,741 $9,000
Q3 2022 Nov 09, 2022	BUY	$0.68 - $2.2 $20,982 - $67,883	30,856 Added 127.27%	55,100 $110,000
Q2 2022 Aug 11, 2022	BUY	$0.74 - $7.44 $17,940 - $180,375	24,244 New	24,244 $18,000
Q4 2020 Feb 10, 2021	SELL	$11.65 - $22.07 $52,984 - $100,374	-4,548 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$8.96 - $14.12 $13,440 - $21,180	1,500 Added 49.21%	4,548 $51,000
Q2 2020 Aug 13, 2020	BUY	$7.27 - $14.18 $22,158 - $43,220	3,048 New	3,048 $41,000
Q4 2019 Feb 10, 2020	SELL	$9.46 - $12.16 $946 - $1,216	-100 Closed	0 $0
Q4 2018 Feb 06, 2019	BUY	$5.69 - $11.28 $569 - $1,128	100 New	100 $1,000

13.9M

200

200

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $33M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

Stay updated on Group One Trading, L.P. with notifications on news.